Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

• Status: Terminated
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Etoposide; Etoposide phosphate; JM 3100; Lenograstim; Plerixafor

Criteria

Inclusion Criteria:

• Have biopsy-confirmed non-Hodgkin lymphoma, of any type

• Must be eligible for autologous transplantation according to institutional guidelines

• Eastern Cooperative Oncology Group performance status of 0 or 1

• Karnofsky performance status of 70 to 100

• Negative for human immunodeficiency virus (HIV)

• prior to the start of mobilization, subjects must have:

• Absolute neutrophil count of >= 1.2 x 10^9/L

• Platelet count of >= 100 x 10^9/L

• Creatinine clearance >= 30 mL/minute

• All patients must be able to comprehend and sign informed consent

• If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy

Exclusion Criteria:

• Have had previous transplants and/or prior mobilization attempts

• Have evidence of progressive non-Hodgkin lymphoma

• Have evidence of bone marrow involvement of lymphoma at time of transplant staging

• Had evidence of active central nervous system (CNS) involvement

• Have had previous radiation of the pelvic area

• Have had prior radioimmunotherapy

• Have received experimental therapy within 2 weeks of enrollment

• Be currently enrolled in another investigational protocol

• Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin